CASTRATION-RESISTANT PROSTATE CANCER
Clinical trials for CASTRATION-RESISTANT PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new CASTRATION-RESISTANT PROSTATE CANCER trials appear
Sign up with your email to follow new studies for CASTRATION-RESISTANT PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Targeted chemo shows promise for Tough-to-Treat prostate cancer
Disease control CompletedThis study tested the chemotherapy drug carboplatin in 16 men with advanced prostate cancer that no longer responds to hormone therapy. The cancer had specific gene changes that might make it sensitive to carboplatin. The goal was to see if the drug could shrink tumors or lower P…
Matched conditions: CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Centre Francois Baclesse • Aim: Disease control
Last updated May 26, 2026 03:23 UTC
-
New drug combo shows promise for Tough-to-Treat prostate cancer
Disease control CompletedThis study tested a combination of two drugs, talazoparib and temozolomide, in 16 men with advanced prostate cancer that had spread and stopped responding to hormone therapy. The goal was to find the safest dose and see if the treatment could shrink tumors. The study was complete…
Matched conditions: CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 26, 2026 03:22 UTC
-
Radioactive therapy shows promise for tough prostate cancer
Disease control CompletedThis study tested a radioactive drug (I-131-1095) that targets prostate cancer cells. It included 120 men whose cancer had stopped responding to the drug abiraterone. Some men received the radioactive drug plus enzalutamide, while others got enzalutamide alone. The main goal was …
Matched conditions: CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Progenics Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 03:13 UTC
-
New oral therapy cycle shows promise for tough prostate cancer
Disease control CompletedThis study tested a new way to treat men with advanced prostate cancer that no longer responds to standard hormone therapy. Fifteen men took high-dose oral testosterone for one week, then no treatment for one week, repeating for three months. If the cancer worsened, they switched…
Matched conditions: CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated May 26, 2026 03:12 UTC
-
New steroid injection may delay chemotherapy for men with tough prostate cancer
Disease control CompletedThis study tested a steroid called triamcinolone in 55 men with castration resistant prostate cancer, a type that stops responding to standard hormone therapy. The goal was to see if a monthly injection could keep the cancer from growing longer than current steroid treatments, wh…
Matched conditions: CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Barts & The London NHS Trust • Aim: Disease control
Last updated May 26, 2026 03:10 UTC
-
Pilot study explores testosterone pulses for resistant prostate cancer
Disease control CompletedThis early-phase study tested whether giving testosterone skin patches in cycles with the drug enzalutamide is possible and safe for men with castration-resistant prostate cancer. Thirty men on standard hormone therapy participated. The goal was to see if at least half of eligibl…
Matched conditions: CASTRATION-RESISTANT PROSTATE CANCER
Phase: EARLY_PHASE1 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated May 19, 2026 11:48 UTC